A national education program for pharmacists funded by the Australian Government under the Quality Use of Diagnostics, Therapeutics and Pathology program.[/caption]
While the evidence bases for both CMs and Schedule 3 sleep aids are unlikely to immediately change, a core practice consideration is the risk-benefit profile of the respective non-prescription sleep aids for the individual patient. 
Is it really insomnia?
Knowledge to practice 
PSA: pharmacists need support to improve Australia’s health
Following the announcement of this year’s Federal Election date, PSA looks forward to working with an incoming Government to support a healthier Australia by...
Migraine and tension-type headache
Case scenario
Chau, a 23-year-old female, requests 'something strong for migraine'. She tells you she is developing a headache, has sensitivity to light and awful...
We must embrace change and lead new models of care
Since becoming National President, I have received significant levels of feedback in support of PSA’s development of pharmacists working in general practice.
I have also...
Collaborate to identify and resolve drug-related problems
An Australian study indicates pharmacists should play a larger role in identifying and resolving drug-related problems (DRPs) as part of a collaborative general practice...
Pharmacist roles and remuneration in the spotlight
Leading lights, up-and-comers and stalwarts of the pharmacy industry will unite in Sydney later this week to discuss how the full potential of pharmacists...
PSA launches bold five-year plan for pharmacy
A new vision for the role of pharmacists launched PSA18 in Sydney today, with the unveiling of PSA’s Pharmacists in 2023: A Discussion Paper,...
